Sep. 20 at 5:17 PM
$SPRY @Exeltrader 😂
The commercial bleed for SPRY Pharmaceuticals is much closer to exhaustion than it is for AQST.
People told me I was crazy-and a degenerate-when I was in
$ASTS with an average cost in the
$3’s. They told me the same thing when I was in
$PLTR at
$16.50.
If ARS Pharmaceuticals craters to
$1 (which is highly unlikely), it doesn’t matter to me. I’ll sit on it for as long as it takes.
Say what you will. I have a thesis, and I’m sticking to it.
$SPRY is definitely out of favor. This asset is cheap in my opinion….undervalued with new leadership at the helm. New CEO and CCO with experience…both worked together at
$MRK and Dynavax, acquired by
$SNY
• Already in 13,000+ U.S. schools
• Gaining market share
• Only needle-free epinephrine treatment currently on the market
• Cash-flow breakeven targeted for 2027.
